FDA
-
-
-
-
-
-
-
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TE
-
-
323,731 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

